EFFECTS OF PREGNANCY ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF GLYBURIDE

妊娠对格列本脲药代动力学和药效学的影响

• 批准号: 7603514
• 负责人: MARY F HEBERT
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603514
• 关键词: Birth trauma; Computer Retrieval of Information on Scientific Projects Database; Control Groups; Diabetic Ketoacidosis; Drug Kinetics; Funding; Gestational Diabetes; Glucose tolerance test; Glyburide; Grant; Hyperinsulinism; Hypertension; Hypoglycemia; Infant; Infection; Institution; Insulin Resistance; Metabolic; Mothers; Neonatal; Non-Insulin-Dependent Diabetes Mellitus; Pharmacodynamics; Polyhydramnios; Pre-Eclampsia; Pregnancy; Pregnant Women; Research; Research Personnel; Resources; Risk; Source; Testing; United States; United States National Institutes of Health; blood glucose regulation; diabetic; response; stillbirth

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Gestational diabetes (GDM) complicates ~4% of all pregnancies in the United States. GDM resembles type 2 diabetes mellitus. Infants born to mothers with GDM are at risk for stillbirth, macrosomia (associated birth injuries), hydramnios and neonatal metabolic complications (e.g. hypoglycemia, insulin resistance, hyperinsulinemia). Mothers are at risk for infections, hypertension, preeclampsia and diabetic ketoacidosis. Tight glucose control reduces risks for mothers and their babies but can be associated with maternal hypoglycemia. Glyburide (GLY) has been used during pregnancy for treatment of GDM however very little is known about the pharmacokinetics (PK) and pharmacodynamics (PD) of this agent during pregnancy. This study will provide the control groups for the glyburide study we are doing in gestational diabetics. We will compare the pharmacokinetics of glyburide in gestational diabetics to type 2 diabetics. We will also compare the response to a mixed meal tolerance test of gestational diabetics with type 2 diabetics and healthy pregnant women with normal glucose tolerance tests.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在美国，妊娠期糖尿病（GDM）的并发症约占所有妊娠的4%。 GDM与2型糖尿病相似。患有GDM的母亲所生的婴儿有死产、巨大儿（相关产伤）、羊水过多和新生儿代谢并发症（如低血糖、胰岛素抵抗、高胰岛素血症）的风险。 母亲有感染、高血压、先兆子痫和糖尿病酮症酸中毒的风险。 严格的血糖控制降低了母亲和婴儿的风险，但可能与母亲低血糖有关。 妊娠期间使用格列本脲（GLY）治疗GDM，但对妊娠期间该药的药代动力学（PK）和药效学（PD）知之甚少。 这项研究将为我们在妊娠期糖尿病患者中进行的格列本脲研究提供对照组。 我们将比较格列本脲在妊娠期糖尿病患者和2型糖尿病患者中的药代动力学。 我们还将比较妊娠期糖尿病患者与2型糖尿病患者和葡萄糖耐量试验正常的健康孕妇对混合餐耐量试验的反应。